Ishita Drugs & Industries Ltd
₹ 74.0
2.90%
24 Jul
- close price
About
Incorporated in 1992, Ishita Drugs & Industries
Ltd is engaged in the manufacturing of various APIs and drug intermediates[1]
Key Points
- Market Cap ₹ 22.1 Cr.
- Current Price ₹ 74.0
- High / Low ₹ 90.8 / 66.0
- Stock P/E 28.4
- Book Value ₹ 38.7
- Dividend Yield 0.00 %
- ROCE 8.66 %
- ROE 6.98 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 1.00% over past five years.
- Company has a low return on equity of 7.72% over last 3 years.
- Earnings include an other income of Rs.0.47 Cr.
- Working capital days have increased from 65.9 days to 146 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.54 | 7.10 | 6.44 | 6.90 | 9.09 | 14.83 | 13.95 | 14.09 | 12.07 | 15.19 | 15.00 | 14.66 | |
| 7.23 | 6.82 | 6.08 | 6.45 | 8.57 | 14.07 | 13.03 | 13.01 | 11.31 | 14.28 | 14.01 | 13.89 | |
| Operating Profit | 0.31 | 0.28 | 0.36 | 0.45 | 0.52 | 0.76 | 0.92 | 1.08 | 0.76 | 0.91 | 0.99 | 0.77 |
| OPM % | 4.11% | 3.94% | 5.59% | 6.52% | 5.72% | 5.12% | 6.59% | 7.67% | 6.30% | 5.99% | 6.60% | 5.25% |
| 0.17 | 0.13 | 0.08 | 0.12 | 0.16 | 0.16 | 0.31 | 0.11 | 0.20 | 0.28 | 0.34 | 0.47 | |
| Interest | 0.04 | 0.06 | 0.04 | 0.11 | 0.06 | 0.03 | 0.03 | 0.02 | 0.05 | 0.09 | 0.07 | 0.06 |
| Depreciation | 0.15 | 0.15 | 0.14 | 0.14 | 0.16 | 0.18 | 0.15 | 0.13 | 0.13 | 0.11 | 0.11 | 0.10 |
| Profit before tax | 0.29 | 0.20 | 0.26 | 0.32 | 0.46 | 0.71 | 1.05 | 1.04 | 0.78 | 0.99 | 1.15 | 1.08 |
| Tax % | 24.14% | 30.00% | 30.77% | 25.00% | 26.09% | 23.94% | 20.95% | 23.08% | 25.64% | 24.24% | 25.22% | 27.78% |
| 0.22 | 0.14 | 0.18 | 0.25 | 0.35 | 0.55 | 0.83 | 0.80 | 0.58 | 0.75 | 0.87 | 0.78 | |
| EPS in Rs | 0.74 | 0.47 | 0.60 | 0.84 | 1.17 | 1.84 | 2.78 | 2.68 | 1.94 | 2.51 | 2.91 | 2.61 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 1% |
| 3 Years: | 7% |
| TTM: | -2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | -1% |
| 3 Years: | 10% |
| TTM: | -10% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 8% |
| 3 Years: | 0% |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 8% |
| 3 Years: | 8% |
| Last Year: | 7% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 |
| Reserves | 2.50 | 2.64 | 2.82 | 3.07 | 3.42 | 3.97 | 4.80 | 5.61 | 6.18 | 6.93 | 7.80 | 8.58 |
| 0.09 | 1.13 | 0.01 | 0.13 | 0.20 | 0.29 | 0.04 | 0.00 | 0.96 | 0.00 | 3.90 | 0.08 | |
| 1.37 | 1.43 | 1.37 | 0.97 | 1.73 | 2.30 | 1.43 | 2.66 | 1.27 | 0.89 | 1.60 | 0.95 | |
| Total Liabilities | 6.95 | 8.19 | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 16.29 | 12.60 |
| 1.26 | 1.11 | 1.02 | 1.19 | 1.30 | 1.14 | 1.00 | 0.88 | 0.89 | 0.80 | 0.88 | 0.88 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.75 |
| Investments | 1.82 | 2.15 | 2.70 | 3.15 | 4.04 | 5.29 | 3.11 | 4.06 | 3.39 | 3.34 | 3.87 | 4.45 |
| 3.87 | 4.93 | 3.47 | 2.82 | 3.00 | 3.12 | 5.15 | 6.32 | 7.12 | 6.67 | 11.54 | 5.52 | |
| Total Assets | 6.95 | 8.19 | 7.19 | 7.16 | 8.34 | 9.55 | 9.26 | 11.26 | 11.40 | 10.81 | 16.29 | 12.60 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 0.26 | 0.52 | 0.72 | 0.79 | 1.05 | -0.67 | 3.08 | -2.90 | 2.12 | -3.64 | 3.92 | |
| -0.34 | -0.28 | -0.55 | -0.69 | -1.06 | -1.15 | 2.45 | -0.93 | 0.59 | 0.13 | -0.67 | -2.24 | |
| -0.07 | 1.07 | -1.05 | 0.05 | 0.09 | 0.09 | -0.24 | 0.00 | 1.05 | -0.87 | 4.33 | -3.81 | |
| Net Cash Flow | -0.29 | 1.05 | -1.08 | 0.08 | -0.19 | -0.01 | 1.54 | 2.14 | -1.25 | 1.38 | 0.02 | -2.13 |
| Free Cash Flow | 0.06 | 0.25 | 0.48 | 0.41 | 0.52 | 1.04 | -0.67 | 3.06 | -3.03 | 2.09 | -3.82 | 2.07 |
| CFO/OP | 35% | 93% | 144% | 160% | 152% | 138% | -73% | 285% | -382% | 233% | -368% | 509% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60.51 | 96.65 | 96.35 | 43.38 | 47.38 | 32.24 | 39.77 | 13.99 | 54.43 | 16.82 | 46.23 | 25.15 |
| Inventory Days | 91.60 | 55.65 | 51.49 | 55.56 | 42.20 | 18.49 | 23.06 | 34.81 | 68.22 | 34.27 | 152.28 | 32.57 |
| Days Payable | 78.31 | 91.07 | 108.49 | 43.21 | 78.70 | 60.25 | 34.76 | 73.22 | 36.67 | 14.87 | 32.44 | 19.83 |
| Cash Conversion Cycle | 73.80 | 61.23 | 39.35 | 55.72 | 10.88 | -9.52 | 28.07 | -24.41 | 85.99 | 36.22 | 166.08 | 37.89 |
| Working Capital Days | 64.38 | 10.28 | 56.68 | 32.27 | 8.03 | -10.83 | 29.83 | -27.46 | 42.94 | 21.87 | 30.17 | 145.65 |
| ROCE % | 5.98% | 4.21% | 4.77% | 7.16% | 8.12% | 10.68% | 14.32% | 12.90% | 8.86% | 10.77% | 9.91% | 8.66% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Purchased KWH |
|
|||||||||
| Foreign Exchange Earnings (Exports) INR |
||||||||||
| Imported Raw Material Share % of total raw material consumed |
||||||||||
| Permanent Employees on Rolls persons |
||||||||||
| R&D Expenditure INR |
||||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Jul - Compliance Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th June, 2026 as attached.
- Closure of Trading Window 27 Jun
-
Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
24 Jun - Related party Ishita Pharmaceuticals acquired 223 shares on June 22, 2026, raising holding to 1.10%.
-
Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011
19 Jun - Related party Ishita Pharmaceuticals acquired 55 shares on June 19, 2026; holding rose to 32,697 shares.
-
Outcome Of Board Meeting Held On 30Th May, 2026
30 May - Board approved audited FY2025-26 results, 33rd AGM notice, and reappointed internal auditors; audit opinion unmodified.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
IDIL is a flagship company of Ishita
Group. It is in the business of manufacturing
and sale of Bulk Drugs, Fine Chemicals, and Intermediates. The company supplies
its products to pharmaceutical companies
in India and abroad